Return to homepagePandemic Pact

Development of reverse genetic systems and mouse model for SARS-CoV-2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R01AI134907-03S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2018
    2023

  • Known Financial Commitments (USD)

    $309,206

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    RICARDO RAJSBAUM

  • Research Location

    United States of America

  • Lead Research Institution

    The University of Texas Medical Branch at Galveston

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The recent epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused globalpublic health emergency. Rapid response to disease control and countermeasure development is a public healthpriority. Reverse genetic systems and animal models are essential tools for studying viral replication,pathogenesis, vaccine development, and antiviral discovery. The goals of this supplement project are to (i)establish the reverse genetic systems and (ii) generate a mouse pathogenesis model for SARS-CoV-2.